Company record
Summit Research Peptides
1 FDA warning letter since 2023 and 0 recalls in the last 12 months.
Get an email the day FDA posts anything new about Summit Research Peptides.
Warning letters
-
DrugsSummit Research Peptides
FDA warned Summit Research Peptides for selling unapproved semaglutide, retatrutide, cagrilintide, tirzepatide, and mazdutide with drug claims.
High risk